Press release – 1st December 2015

4P_logo_B

4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement

 

Montpellier, December 1st 2015

 

In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.

 

axlrsattp307-12cm      enscm     logo_cnrs_transparent    montpellier   4P_logo_B

 

EN: Press release 4P Pharma-SATT AxLR 011215

FR: Communiqué de presse 4P Pharma-SATT AxLR 011215 Press release 4P Pharma-SATT AxLR 011215

 

PRESS CONTACTS:

4P Pharma

Revital Rattenbach

1 rue du Professeur Calmette, 59000 Lille

revital@4p-pharma.com

Tel: +33 (0)9 50 72 97 68


Université de Montpellier

Anne Delestre
CC 07-003 Place Eugène Bataillon, 34095 Montpellier cedex 5

anne.delestre@umontpellier.fr

Tel: +33 (0)4 34 43 31 93

 

 

CNRS

Aurélie Lieuvin

1919 route de Mende, 34293 Montpellier cedex 5

aurelie.Lieuvin@dr13.cnrs.fr

Tel: +33 (0)4 67 61 35 10

 

 AxLR SATT

Franck-Léopold Erstein

1000, Avenue Agropolis, 34394 Montpellier cedex 5

fle@axlr.com

Tel: +33 (0)6 07 28 21 43